Pacific Biosciences Acquires Omniome
July 20, 2021
Pacific Biosciences (PacBio) signed a definitive agreement to acquire San Diego-based Omniome for approximately $600 million in upfront consideration (9.4 million PacBio shares plus $300 million cash) plus up to $200 million in cash and stock tied to milestones, valuing the deal at about $800 million. The deal — supported by a concurrent $300 million PIPE financing — brings Omniome’s high-accuracy short-read Sequencing-by-Binding technology into PacBio’s portfolio of high-accuracy long-read SMRT sequencing systems to expand PacBio’s capabilities and address high-growth clinical markets such as oncology, transcriptomics and NIPT.
- Buyers
- Pacific Biosciences of California, Inc. (PacBio)
- Targets
- Omniome
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Pacific Biosciences Acquires Apton Biosystems
August 2, 2023
Biotechnology
Pacific Biosciences (PacBio) has entered into an agreement to acquire Apton Biosystems, a Pleasanton, California-based developer of high-throughput short-read sequencing instrumentation, to accelerate development of a next-generation, high-throughput short-read sequencer. The all-stock deal provides approximately $85 million upfront (≈6.3M shares) plus up to $25 million in additional consideration contingent on achieving $50 million in revenue, valuing the transaction at up to ~$110 million.
-
Twist Bioscience Acquires iGenomX
June 30, 2021
Biotechnology
Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.
-
Illumina Acquires SomaLogic from Standard BioTools
January 30, 2026
Biotechnology
Illumina has completed its acquisition of SomaLogic from Standard BioTools for $350 million in cash plus up to $75 million in near-term performance-based payments, adding SomaLogic's proteomics capabilities to Illumina's multiomics strategy. The deal expands Illumina's ability to integrate SomaLogic's SomaScan platform with its NGS ecosystem, DRAGEN software, and Illumina Connected Multiomics to accelerate proteomics at scale while Standard BioTools receives upfront cash, potential earnouts and ongoing royalties.
-
Bionano Genomics Acquires BioDiscovery
October 12, 2021
Software
Bionano Genomics agreed to acquire BioDiscovery, a provider of NxClinical genomics analysis software, in a deal worth up to $100 million in cash and equity. The acquisition will integrate BioDiscovery's platform-agnostic analysis and reporting tools with Bionano's optical genome mapping technology to accelerate variant analysis and broaden Bionano's market reach; BioDiscovery founder Soheil Shams will join Bionano as Chief Informatics Officer.
-
Bionano Genomics Acquires Purigen Biosystems
November 28, 2022
Biotechnology
Bionano Genomics agreed to acquire Purigen Biosystems to integrate Purigen's isotachophoresis (ITP) Ionic Purification System into Bionano's optical genome mapping (OGM) workflow, aiming to simplify ultra-high molecular weight (UHMW) DNA isolation and address difficult sample types. The deal consideration is up to $64 million (including $32 million cash at closing and milestone-contingent payments) and was expected to close by December 8, 2022.
-
Tome Biosciences Acquires Replace Therapeutics
January 5, 2024
Biotechnology
Tome Biosciences has acquired Replace Therapeutics in a merger valued at $65 million in up-front and near-term milestones and up to $185 million total through a mix of cash and stock. Replace will become a wholly owned subsidiary of Tome, adding its ligase-mediated programmable genomic integration (L-PGI) technology to complement Tome's large-DNA integrase-mediated PGI platform to expand the company's gene‑editing capabilities.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.